Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2018

View Archived Issues

New path to RAS activation discovered

New anti-inflammation target has similarities, and differences, to PARP

Weekly and monthly Buvidal approved in Europe for opioid dependence

CV-6-168, a dUTPase inhibitor that sensitizes multiple cancer types to TS-targeted therapies

European Commission grants approval for Apealea as anticancer combination therapy

TAS-0612, a first-in-class RSK-AKT-S6K inhibitor for the treatment of chemoresistant cancers

Dual FXR, TGR5 knockout mice can be used to study liver fibrosis

Positive topline data presented from a phase I study of LTX-315

Sensorion signs letter of intent with Institut Pasteur for hearing loss gene therapy programs

MIW-815 shows promise in phase I study in patients with advanced solid tumors or lymphomas

Responses seen with anti-PD-1 monoclonal antibody INCMGA-00012 in expanded phase I study

Dimerix begins dosing in phase II trials of DMX-200 for kidney disease

Novo Nordisk reports topline data from Japanese study of oral semaglutide for type 2 diabetes

Adial engages CRO to oversee phase III trial of AD-04 for alcohol use disorder

Astellas and Juventas sign option and license agreement for gene therapy JVS-100

European Commission approves Luxturna for RPE65 mutation-associated retinal dystrophy

Evotec and Immuneering collaborate on AI-led drug discovery for metabolic diseases

NEW-HOPE data show firibastat efficacy and safety in diverse hypertensive population

First clinical data for MAb IT-1208 presented

Syros presents preliminary phase I data for SY-1365

SRA-141 demonstrates favorable PK profile and excellent antitumor activity in vivo

AST-008 shown to be safe and potent innate immune activator in phase I study

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...